Advertisement

Familial Cancer

, Volume 18, Issue 3, pp 359–362 | Cite as

Progress report: familial pancreatic cancer

  • Ioannis MintzirasEmail author
  • Detlef K. Bartsch
Review

Abstract

A hereditary predisposition to pancreatic ductal adenocarcinoma (PDAC) is reported in approximately 5% of patients. Familial pancreatic cancer (FPC) accounts for the vast majority of hereditary PDAC cases. FPC defines families with two or more affected first-degree relatives with PDAC that do not fulfil the criteria of any other inherited tumor syndrome or families with PDAC in three or more relatives of any degree. The current progress report focuses on the knowledge of FPC with regard to molecular pathogenesis, clinical and molecular diagnosis, surveillance and novel treatment options reported in the last 5 years.

Keywords

Familial pancreatic cancer Screening Molecular pathogenesis Treatment 

Notes

References

  1. 1.
    Bartsch DK, Gress TM, Langer P (2012) Familial pancreatic cancer—current knowledge. Nat Rev Gastroenterol Hepatol 9(8):445–453CrossRefGoogle Scholar
  2. 2.
    Canto MI, Harinck F, Hruban RH et al (2013) International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 62(3):339–347CrossRefGoogle Scholar
  3. 3.
    Schneider R, Slater EP, Sina M et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10(2):323–330CrossRefGoogle Scholar
  4. 4.
    Bartsch DK, Dietzel K, Bargello M et al (2013) Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 12(1):89–96CrossRefGoogle Scholar
  5. 5.
    Vasen H, Ibrahim I, Ponce CG et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol 34(17):2010–2019CrossRefGoogle Scholar
  6. 6.
    Potjer TP, Schot I, Langer P et al (2013) Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 19(2):442–449CrossRefGoogle Scholar
  7. 7.
    Zhen DB, Rabe KG, Gallinger S et al (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17(7):569–577.  https://doi.org/10.1038/gim.2014.153 CrossRefGoogle Scholar
  8. 8.
    Yang XR, Rotunno M, Xiao Y et al (2016) Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Hum Genet 135(11):1241–1249CrossRefGoogle Scholar
  9. 9.
    Roberts NJ, Norris AL, Petersen GM et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166–175CrossRefGoogle Scholar
  10. 10.
    Smith AL, Alirezaie N, Connor A et al (2016) Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Lett 370(2):302–312CrossRefGoogle Scholar
  11. 11.
    Takai E, Yachida S, Shimizu K et al (2016) Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget 7(45):74227–74235CrossRefGoogle Scholar
  12. 12.
    Lener MR, Kashyap A, Kluźniak W et al (2017) The prevalence of founder mutations among individuals from families with familial pancreatic cancer syndrome. Cancer Res Treat 49(2):430–436CrossRefGoogle Scholar
  13. 13.
    Slavin TP, Neuhausen SL, Nehoray B et al (2018) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer 17(2):235–245CrossRefGoogle Scholar
  14. 14.
    Chaffee KG, Oberg AL, McWilliams RR et al (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20(1):119–127CrossRefGoogle Scholar
  15. 15.
    Slater EP, Langer P, Fendrich V et al (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9(3):335–343CrossRefGoogle Scholar
  16. 16.
    Grant RC, Denroche RE, Borgida A et al (2018) Exome-wide association study of pancreatic cancer risk. Gastroenterology 154(3):719–722CrossRefGoogle Scholar
  17. 17.
    Canto MI, Almario JA, Schulick RD et al (2018) Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterology 155(3):740–751CrossRefGoogle Scholar
  18. 18.
    Corral JE, Mareth KF, Riegert-Johnson DL et al (2018) Diagnostic yield from screening asymptomatic individuals at high risk for pancreatic cancer: a meta-analysis of cohort studies. Clin Gastroenterol Hepatol 17(1):41–53.  https://doi.org/10.1016/j.cgh.2018.04.065 CrossRefGoogle Scholar
  19. 19.
    Brune KA, Lau B, Palmisano E et al (2010) Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 102(2):119–126CrossRefGoogle Scholar
  20. 20.
    Bartsch DK, Slater EP, Carrato A et al (2016) Refinement of screening for familial pancreatic cancer. Gut 65(8):1314–1321CrossRefGoogle Scholar
  21. 21.
    Harinck F, Konings IC, Kluijt I et al (2016) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 65(9):1505–1513CrossRefGoogle Scholar
  22. 22.
    Bartsch DK, Gercke N, Strauch K et al (2018) The combination of MiRNA-196b, LCN2, and TIMP1 is a potential set of circulating biomarkers for screening individuals at risk for familial pancreatic cancer. J Clin Med 7(10):E295.  https://doi.org/10.3390/jcm7100295 CrossRefGoogle Scholar
  23. 23.
    Melo SA, Luecke LB, Kahlert C et al (2015) Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523(7559):177–182CrossRefGoogle Scholar
  24. 24.
    Suenaga M, Yu J, Shindo K et al (2018) Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance. Clin Cancer Res 24(12):2963–2974CrossRefGoogle Scholar
  25. 25.
    Potjer TP, Mertens BJ, Nicolardi S et al (2016) Application of a serum protein signature for pancreatic cancer to separate cases from controls in a pancreatic surveillance cohort. Transl Oncol 9(3):242–247.  https://doi.org/10.1016/j.tranon.2016.03.003 CrossRefGoogle Scholar
  26. 26.
    Potjer TP, Bartsch DK, Slater EP et al (2015) Limited resection of pancreatic cancer in high-risk patients can result in a second primary. Gut 64(8):1342–1344.  https://doi.org/10.1136/gutjnl-2015-309568 CrossRefGoogle Scholar
  27. 27.
    Fogelman D, Sugar EA, Oliver G et al (2015) Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76(3):489–498CrossRefGoogle Scholar
  28. 28.
    Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Visceral-, Thoracic- and Vascular SurgeryPhilipps-University MarburgMarburgGermany

Personalised recommendations